Our study highlights an interaction among CD8+ T cells infiltration, PD-L1 expression, and CD44+/CD133+ CSCs existence, thus providing a rationale for designing ideal combination cancer therapies based on tumor immunology. The gene discussed is CD8A; the disease is cancer.